Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

Internal and Emergency Medicine

Volumn 11, Issue 1, 2016, Pages 123-140

  Mantarro, Stefania ^a   Rossi, Marta ^b,c   Bonifazi, Martina ^b   D’Amico, Roberto ^d   Blandizzi, Corrado ^a   La Vecchia, Carlo ^c   Negri, Eva ^b   Moja, Lorenzo ^c,e  

^a UNIVERSITY OF PISA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Cardiotoxicity; Early breast cancer; Heart failure; Meta analysis; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; COMPLICATION; FEMALE; HUMAN; META ANALYSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; TRASTUZUMAB;

EID: 84958109484     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-015-1362-x     Document Type: Article

References (87)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712
3. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26(35):5697–5704. doi:10.1200/JCO.2007.15.8659
4. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243. doi:10.1002/14651858.CD006243.pub2
5. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D’Amico R (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 6:CD006242. doi:10.1002/14651858.CD006242.pub2
6. Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22(2):322–329. doi:10.1200/JCO.2004.01.120
7. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A (2013) 6 versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748. doi:10.1016/s1470-2045(13)70225-0
8. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA (2013) Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141(3):461–470. doi:10.1007/s10549-013-2697-5
9. Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E (2013) Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist 18(7):795–801. doi:10.1634/theoncologist.2013-0065
10. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M. D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107–4115. doi:10.1200/jco.2005.04.9551
11. Gianni L, Salvatorelli E, Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7(2):67–71. doi:10.1007/s12012-007-0013-5
12. Administration FaD (1998) HERCEPTIN (trastuzumab) Label—FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf. Accessed 31 Jan 2014
13. Agency EM (2010) Herceptin: EPAR—product information. EMA http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf. Accessed 31 Jan 2014
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC) v (June 14, 2010) National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 31 Jan 2014
15. New York Heart Association (NYHA) classification: classes of heart failure. http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp. Accessed 31 Jan 2014
16. Anand IS, Florea VG, Fisher L (2002) Surrogate end points in heart failure. J Am Coll Cardiol 39(9):1414–1421
17. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231–1238. doi:10.1200/jco.2007.13.5467
18. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819. doi:10.1200/jco.2005.02.4091
19. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146–152
20. Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4):404–413. doi:10.1093/biomet/26.4.404
21. Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Ann Math Stat 21(4):607–611. doi:10.1214/aoms/1177729756
22. Trikalinos TA, Trow P, Schmid CH (2013) Simulation-based comparison of methods for meta-analysis of proportions and rates. Agency for Healthcare Research and Quality (US), Rockville, MD 13(14):EHC084-EF
23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
24. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
25. Aitelhaj M, Lkhouyaali S, Rais G, Mohtaram A, Raissouni S, Ghissassi B, Boutayeb S, Mrabti H, Bensouda Y, Errihani H (2013) Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. BMC Res Notes 6:339. doi:10.1186/1756-0500-6-339
26. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F (2012) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385–2393. doi:10.1002/cncr.26555
27. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305. doi:10.1093/jnci/djs317
28. Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Menard S, Tagliabue E (2013) Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat 141(1):101–110. doi:10.1007/s10549-013-2658-z
29. Caussa L, Kirova YM, Gault N, Pierga JY, Savignoni A, Campana F, Dendale R, Fourquet A, Bollet MA (2011) The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 47(1):65–73. doi:10.1016/j.ejca.2010.08.013
30. Cha C, Ahn SG, Lee HM, Lee HW, Lee SA, Jeong J (2013) Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis. Oncology 85(4):228–234. doi:10.1159/000354836
31. Chan A, McGregor SR (2012) Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab. Intern Med J 42(3):267–274. doi:10.1111/j.1445-5994.2011.02432.x
32. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F (2011) Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 130(3):845–854. doi:10.1007/s10549-011-1714-9
33. Cook TS, S, Plana JC, Oliveira G, Budd GT, Marwick T (2011) Cardioprotective effect of beta-blockers and ACE-inhibitors in breast cancer patients treated with trastuzumab: a follow-up study of heart failure and cardiac function over 12 months. Circulation 124 (21 Suppl):A13988
34. Dall PL, G, Göhler T, Feisel-Schwickeradi G, Koch T, Heilmann V, Schindler C, Wilke J, Tesch H, Selbach J, Eggert J, Hinke A (2013) Trastuzumab treatment of early breast cancer: long-term results from a prospective observation study, including a large cohort of elderly patients. Abstracts from the 36th Annual SABCS
35. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10:5. doi:10.1186/1532-429x-10-5
36. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99(9):634–639. doi:10.1136/heartjnl-2012-303151
37. Freedman RVDL, IM, Lin N, Lii J, Winer EP, Keating Lynn N (2013) Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). J Clin Oncol 31(15 Suppl), abstract 616
38. Fried G, Regev T, Moskovitz M (2013) Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat 142(1):1–7. doi:10.1007/s10549-013-2732-6
39. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377–384. doi:10.1016/s0140-6736(09)61964-4
40. Guglin M, Hartlage G, Reynolds C, Chen R, Patel V (2009) Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail 15(8):651–657. doi:10.1016/j.cardfail.2009.04.011
41. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, Lindquist DL, Holmes FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O’Shaughnessy J (2013) Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 14(11):1121–1128. doi:10.1016/s1470-2045(13)70384-x
42. Nag D, Ferrusi I, Khong H, Earle C, Trudeau M, Marshall D, Leighl N (2012) Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer. Cancer Res 72(24 Supplement):471s. doi:10.1158/0008-5472.SABCS12-P5-18-14
43. Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S (2011) Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer 11(2):93–102. doi:10.1016/j.clbc.2011.03.001
44. Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, Banach M (2012) Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2—a prospective study. Arch Med Sci 8(2):227–235. doi:10.5114/aoms.2012.28549
45. Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L, Richel DJ (2012) Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol 23(7):1780–1788. doi:10.1093/annonc/mdr519
46. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14(12):1183–1192. doi:10.1016/s1470-2045(13)70411-x
47. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J, BCIRG 006 Investigators (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94(1 Supplement):s5
48. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134. doi:10.1200/jco.2009.23.0946
49. Subar M, Lin W, Chen W, Pittman DG (2011) Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J 17(4):383–390. doi:10.1111/j.1524-4741.2011.01101.x
50. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25):3859–3865. doi:10.1200/jco.2006.09.1611
51. Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F, Ceccherini R, Bovelli D, Lestuzzi C, Cioffi G (2012) Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 23(12):3058–3063. doi:10.1093/annonc/mds127
52. Tolaney SB, WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Res 73(24 Suppl), abstract S1-04. doi:10.1158/0008-5472.SABCS13-S1-04
53. Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S (2012) Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. J Cancer Res Clin Oncol 138(12):2145–2151. doi:10.1007/s00432-012-1296-x
54. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351–3357. doi:10.1200/jco.2010.31.4930
55. Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, Walker JR, Lister D, Arora RC, Barac I, Morris A, Jassal DS (2009) Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 117(2):357–364. doi:10.1007/s10549-008-0260-6
56. Yamamoto NY, H, Iwata H, Masuda N, Ohtani S, Takahashi M, Yamazaki K, Kato M, Ohno S, Kuroi K, Yamagami K, Morimoto,T, Hasegawa Y, Takano T, Kadoya T, Hosoda M, Abe H, Morita S, Yasuno S, Toi M (2013) Safety of trastuzumab in HER2-positive primary breast cancer in Japan: INITIAL safety report for the large-scale cohort study (JBCRG C-01). J Clin Oncol 31 (15 (suppl; abstr 613))
57. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sorensen PG, Moller S, Bergh J, Langkjer ST (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29(3):264–271. doi:10.1200/jco.2010.30.8213
58. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):2162–2171. doi:10.1200/jco.2005.01.014
59. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. doi:10.1056/NEJMoa1113216
60. De La Pena LC J, Manikhas A, Roman L, Semiglazov V, Biakhov MY, Dasappa L, Llombart A, Rozencweig M, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis C, Baselga J (2013) Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2 + metastatic breast cancer (MBC). J Clin Oncol 31 (15 Suppl), abstract 517
61. Esposito A, Munzone E, Bagnardi V, Adamoli L, Sciandivasci A, Cullura D, Goldhirsch A, Nole F (2012) Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients? Anticancer Drugs 23(10):1089–1098. doi:10.1097/CAD.0b013e32835679d3
62. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8):799–809. doi:10.1634/theoncologist.2009-0029
63. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5(1):52–58 (discussion 59–62)
64. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V (2013) AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719–1725. doi:10.1200/jco.2012.44.7912
65. John M, Hinke A, Stauch M, Wolf H, Mohr B, Hindenburg HJ, Papke J, Schlosser J (2012) Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines—a phase II multipractice study. BMC Cancer 12:165. doi:10.1186/1471-2407-12-165
66. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529–5537. doi:10.1200/jco.2008.20.6847
67. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135(3):875–883. doi:10.1007/s10549-012-2209-z
68. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792. doi:10.1200/jco.2005.04.1764
69. Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, An X, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG (2012) Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Med Oncol 29(1):39–47. doi:10.1007/s12032-010-9798-3
70. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/nejm200103153441101
71. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22(6):1063–1070. doi:10.1200/jco.2004.06.557
72. Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R, du Bois A, Harbeck N, Jackisch C, Muller V, Pauschinger M, Thomssen C, Lehle M, Catalani O, Luck HJ (2010) First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 28(9):1473–1480. doi:10.1200/jco.2009.21.9709
73. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29(2):149–156. doi:10.1200/jco.2010.28.6450
74. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726
75. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fatima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28(6):976–983. doi:10.1200/jco.2008.21.6531
76. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nole F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916. doi:10.1200/jco.2009.27.3615
77. Du XL, Xia R, Burau K, Liu CC (2011) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol 28(Suppl 1):S80–S90. doi:10.1007/s12032-010-9717-7
78. Huszno J, Les D, Sarzyczny-Slota D, Nowara E (2013) Cardiac side effects of trastuzumab in breast cancer patients—single centere experiences. Contemp Oncol (Pozn) 17(2):190–195. doi:10.5114/wo.2013.34624
79. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640. doi:10.1016/s0140-6736(11)61847-3
80. Sun X, Briel M, Walter SD, Guyatt GH (2010) Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340:c117. doi:10.1136/bmj.c117
81. National Cancer Institute. Cancer of the breast. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 27 Sept 2015
82. Golder S, Loke YK, Bland M (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 8(5):e1001026. doi:10.1371/journal.pmed.1001026
83. Ezaz G, Long JB, Gross CP, Chen J (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472. doi:10.1161/JAHA.113.000472
84. Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, Wu Z, Wu S (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37(4):312–320. doi:10.1016/j.ctrv.2010.09.001
85. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141. doi:10.1056/NEJMoa1406281
86. Albini A, Cesana E, Donatelli F, Cammarota R, Bucci EO, Baravelli M, Anza C, Noonan DM (2011) Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol 7(5):693–704. doi:10.2217/fca.11.54
87. Hamza TH, van Houwelingen HC, Stijnen T (2008) The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61(1):41–51. doi:10.1016/j.jclinepi.2007.03.016